Fujian Haixi Pharmaceuticals Shares Surge 36% in Hong Kong IPO
Hong Kong – Shares of Fujian Haixi Pharmaceuticals Co. jumped as much as 36% in their Hong Kong stock exchange debut Monday, signaling robust investor appetite for new listings in the city. The Chinese drugmaker’s stock reached a high of HK$117.80 (US$15.16) before settling at a 27% increase over its initial public offering price of HK$86.40.
The company successfully raised HK$993.6 million (approximately US$127.3 million) through the sale of 11.5 million shares. Demand for the offering was exceptionally high, with the Hong Kong portion of the sale oversubscribed by more than 3,165 times and the international offering oversubscribed by 6.3 times.
Huatai Financial Holdings and CMB International served as joint sponsors for the IPO. The strong performance of Fujian Haixi Pharmaceuticals underscores a broader trend: Hong Kong has become a particularly active IPO market this year. Through the first nine months of 2025, funds raised via initial public offerings totaled HK$182.9 billion, a substantial increase compared to the HK$55.6 billion raised during the same period in 2024, according to data from the Hong Kong stock exchange.
